Health-related QoL in Alpha-1 Antitrypsin Deficiency-Associated COPD - COPD: Peer Perspectives Medpage Today - 15 Apr 2024 Health-related QoL in Alpha-1 Antitrypsin Deficiency-Associated COPD - COPD: Peer Perspectives ... More
Alpha-1 antitrypsin protects against phosgene-induced acute lung injury by activating the ID1-dependent anti ... ScienceDirect.com - 15 Oct 2023 Alpha-1 antitrypsin protects against phosgene-induced acute lung injury by activating the ID1-dependent anti ... ... More
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of ... Yahoo Finance - 26 Mar 2024 Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of ... ... More
Alpha-1 Antitrypsin Deficiency Market to Register Incremental Growth by 2032, Assesses DelveInsight | Key ... PR Newswire - 18 Jan 2024 Alpha-1 Antitrypsin Deficiency Market to Register Incremental Growth by 2032, Assesses DelveInsight | Key ... ... More
Sanofi bets $1.7b on potential best-in-class rare disease therapy European Pharmaceutical Review - 24 Jan 2024 Sanofi bets $1.7b on potential best-in-class rare disease therapy ... More
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Trends Suggest A USD 2517 Million Valuat PharmiWeb.com - 18 Apr 2024 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Trends Suggest A USD 2517 Million Valuat ... More
New spinout to develop gene therapies targeting rare lung diseases | Imperial News Imperial College London - 14 Sep 2023 New spinout to develop gene therapies targeting rare lung diseases | Imperial News ... More
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin ... GlobeNewswire - 23 Jan 2024 Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin ... ... More
UK clearance for phase I/II trial of Beam's BEAM-302 for α1-antitrypsin deficiency BioWorld MedTech - 27 Mar 2024 UK clearance for phase I/II trial of Beam's BEAM-302 for α1-antitrypsin deficiency ... More
Alpha 1 Antitrypsin Deficiency Facts & Resources CSL - 01 Jun 2023 Alpha 1 Antitrypsin Deficiency Facts & Resources ... More
Increased expression or activation of TRPML1 reduces hepatic storage of toxic Z alpha-1 antitrypsin ScienceDirect.com - 06 Sep 2023 Increased expression or activation of TRPML1 reduces hepatic storage of toxic Z alpha-1 antitrypsin ... More
CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA® [Alpha1 ... PR Newswire - 02 Jan 2024 CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA® [Alpha1 ... ... More
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA ... Yahoo Finance - 06 Dec 2023 Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA ... ... More
Testing Patterns and Disparities for Alpha-1 Antitrypsin Deficiency ScienceDirect.com - 13 Jul 2023 Testing Patterns and Disparities for Alpha-1 Antitrypsin Deficiency ... More
Explainer: What Are Symptoms of Alpha 1? CSL - 09 Jun 2023 Explainer: What Are Symptoms of Alpha 1? ... More
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States ... PR Newswire - 19 Sep 2023 Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States ... ... More
European Respiratory Society International Congress 2023 CSL - 08 Sep 2023 European Respiratory Society International Congress 2023 ... More
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency PR Newswire - 30 May 2023 Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency ... More